首站-论文投稿智能助手
典型文献
Alternative mix-and-match COVID-19 vaccine administration versus standard vaccination for prevention of severe COVID-19:A specific cost utility analysis
文献摘要:
Till now,over 220 million people throughout the world have already been affected by coronavirus disease(COVID-19).Vaccination is the most effective strategy to prevent the spread of COVID-19[1].Several pharmaceutical companies have announced the success of their COVID-19 vaccine study.Additional publications on the vaccine1s efficacy and inoculation costs are available.When it comes to a new immunization,the cost and accessibility of the vaccine are crucial considerations[2].In most cases,it is necessary to administer two intramuscular vaccine doses.While some scientists provide strategies for reducing the risk and overcoming the problem of insufficient COVID-19 vaccination supply by administering COVID-19 in a different way.Hence,a concern on utility of the new COVID-19 vaccine should be able to prevent overall COVID-19 and severe infection.The efficacy of COVID-19 vaccinations has been decreased due to the introduction of new variations of concern.
文献关键词:
作者姓名:
Rujittika Mungmunpuntipantip;Viroj Wiwanitkit
作者机构:
Private Academic Consultant,Bangkok,Thailand;Dr DY Patil University,Pune,India;Hainan Medical University,Haikou,China
引用格式:
[1]Rujittika Mungmunpuntipantip;Viroj Wiwanitkit-.Alternative mix-and-match COVID-19 vaccine administration versus standard vaccination for prevention of severe COVID-19:A specific cost utility analysis)[J].亚太热带医药杂志(英文版),2022(02):93-94
A类:
vaccine1s
B类:
Alternative,mix,match,administration,versus,standard,prevention,severe,specific,utility,analysis,Till,now,million,people,throughout,world,have,already,been,affected,by,coronavirus,disease,Vaccination,most,effective,strategy,spread,Several,pharmaceutical,companies,announced,success,their,study,Additional,publications,efficacy,inoculation,costs,are,available,When,comes,new,immunization,accessibility,crucial,considerations,In,cases,necessary,two,intramuscular,doses,While,some,scientists,provide,strategies,reducing,risk,overcoming,problem,insufficient,supply,administering,different,way,Hence,concern,should,overall,infection,vaccinations,has,decreased,due,introduction,variations
AB值:
0.611313
相似文献
Knowledge about,attitude and acceptance towards,and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China:A cross-sectional survey
Jing Hong;Xiao-wan Xu;Jing Yang;Jing Zheng;Shu-mei Dai;Ju Zhou;Qing-mei Zhang;Yi Ruan;Chang-quan Ling-School of Traditional Chinese Medicine,Naval Medical University,Shanghai 200433,China;Department of Integrative Oncology,Changhai Hospital,Naval Medical University,Shanghai 200433,China;Department of Oncology,The First Affiliated Hospital,Bengbu Medical College,Bengbu 233010,Anhui Province,China;Department of Nursing,Fuyang Cancer Hospital,Fuyang 236000,Anhui Province,China;Department of Cardiac Rehabilitation,Shanghai First Rehabilitation Hospital,Shanghai 200090,China;Department of Radiation Oncology,Anhui Chest Hospital,Hefei 230022,Anhui Province,China;Department of Anesthesiology,Chaohu Hospital,Anhui Medical University,Hefei 238000,Anhui Province,China
Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination
Xuan Li;Nuttapong Wichai;Jiabao Wang;Xiuping Liu;Huimin Yan;Yu Wang;Mingchi Luo;Shengyuan Zhou;Kai Wang;Lin Li;Lin Miao-State Key Laboratory of Component-based Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin,China;Institute of Traditional Chinese Medicine,Tianjin University ofTraditional Chinese Medicine,Tianjin,China;Faculty of Pharmacy,Mahasarakham University,Mahasarakham,Thailand;Institute of Traditional Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin,China;Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae,Ministry of Education,Tianjin University of Traditional Chinese Medicine,Tianjin,China;Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Seroprevalence of influenza viruses in Shandong,Northern China during the COVID-19 pandemic
Chuansong Quan;Zhenjie Zhang;Guoyong Ding;Fengwei Sun;Hengxia Zhao;Qinghua Liu;Chuanmin Ma;Jing Wang;Liang Wang;Wenbo Zhao;Jinjie He;Yu Wang;Qian He;Michael J.Carr;Dayan Wang;Qiang Xiao;Weifeng Shi-Key Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong,Shandong First Medical University&Shandong Academy of Medical Sciences,Taian 271000,China;School of Public Health,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117,China;The Department of Infectious Disease,The Second Affiliated Hospital of Shandong First Medical University,Taian 271000,China;Clinical Laboratory,The Department of Clinical Laboratory,Boshan District Hospital,Zibo 255200,China;Clinical Laboratory,The Department of Clinical Laboratory,The Second Affiliated Hospital of Shandong First Medical University,Taian 271000,China;The Department of Cancer Center,Taian Tumor Prevention and Treatment Hospital,Taian 271000,China;National Virus Reference Laboratory,School of Medicine,University College Dublin,Dublin 4,Ireland;International Collaboration Unit,International Institute for Zoonosis Control,Hokkaido University,Sapporo,Hokkaido,001-0020,Japan;Chinese National Influenza Center,National Institute for Viral Disease Control and Prevention,Collaboration Innovation Center for Diagnosis and Treatment of Infectious Diseases,Chinese Center for Disease Control and Prevention,Key Laboratory for Medical Virology,National Health and Family Planning Commission,Beijing 102206,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。